Header Logo

Connection

PAVAN REDDY to Bone Marrow Transplantation

Back to Details
This is a "connection" page, showing publications PAVAN REDDY has written about Bone Marrow Transplantation.
PAVAN REDDY
Connection Strength
6.502
Bone Marrow Transplantation
  1. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation. J Immunol. 2018 12 01; 201(11):3443-3455.
    View in: PubMed
    Score: 0.473
  2. Selected Reviews from the 2016 BMT Tandem Meetings. Biol Blood Marrow Transplant. 2016 Mar; 22(3 Suppl):S1-2.
    View in: PubMed
    Score: 0.393
  3. Host CD8a+ dendritic cells may be a key factor for separating graft-versus-host disease from graft-versus-leukemia. Biol Blood Marrow Transplant. 2015 Apr; 21(4):775-6.
    View in: PubMed
    Score: 0.364
  4. Mouse models in bone marrow transplantation and adoptive cellular therapy. Semin Hematol. 2013 Apr; 50(2):131-44.
    View in: PubMed
    Score: 0.326
  5. Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood. 2013 May 16; 121(20):4231-41.
    View in: PubMed
    Score: 0.321
  6. Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. J Leukoc Biol. 2012 Apr; 91(4):667-75.
    View in: PubMed
    Score: 0.296
  7. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012 Jan 10; 109(2):564-9.
    View in: PubMed
    Score: 0.294
  8. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood. 2012 Apr 19; 119(16):3844-53.
    View in: PubMed
    Score: 0.292
  9. Host basophils are dispensable for induction of donor T helper 2 cell differentiation and severity of experimental graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1747-53.
    View in: PubMed
    Score: 0.288
  10. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res. 2011 Jan 01; 17(1):77-88.
    View in: PubMed
    Score: 0.272
  11. Mouse models of bone marrow transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):129-35.
    View in: PubMed
    Score: 0.223
  12. A novel role for the semaphorin Sema4D in the induction of allo-responses. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1294-1303.
    View in: PubMed
    Score: 0.219
  13. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007 Oct; 150(4):197-214.
    View in: PubMed
    Score: 0.216
  14. Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease. Exp Hematol. 2007 Feb; 35(2):274-86.
    View in: PubMed
    Score: 0.210
  15. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood. 2004 Nov 15; 104(10):3393-9.
    View in: PubMed
    Score: 0.176
  16. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003 Apr 01; 101(7):2877-85.
    View in: PubMed
    Score: 0.157
  17. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood. 2002 Nov 01; 100(9):3429-31.
    View in: PubMed
    Score: 0.156
  18. miR-142 controls metabolic reprogramming that regulates dendritic cell activation. J Clin Invest. 2019 04 08; 129(5):2029-2042.
    View in: PubMed
    Score: 0.122
  19. Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition. Nat Microbiol. 2019 05; 4(5):800-812.
    View in: PubMed
    Score: 0.121
  20. Survival signal REG3a prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. J Clin Invest. 2018 11 01; 128(11):4970-4979.
    View in: PubMed
    Score: 0.117
  21. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat Commun. 2018 09 10; 9(1):3674.
    View in: PubMed
    Score: 0.117
  22. Murine Models of Steroid Refractory Graft-versus-Host Disease. Sci Rep. 2018 08 20; 8(1):12475.
    View in: PubMed
    Score: 0.117
  23. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016 05; 17(5):505-513.
    View in: PubMed
    Score: 0.099
  24. Mature T cell responses are controlled by microRNA-142. J Clin Invest. 2015 Jul 01; 125(7):2825-40.
    View in: PubMed
    Score: 0.094
  25. BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 2015 Apr 23; 125(17):2724-8.
    View in: PubMed
    Score: 0.092
  26. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood. 2014 May 29; 123(22):3512-23.
    View in: PubMed
    Score: 0.086
  27. Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. J Clin Invest. 2013 Nov; 123(11):4739-54.
    View in: PubMed
    Score: 0.084
  28. A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease. J Immunol. 2010 Oct 01; 185(7):3866-72.
    View in: PubMed
    Score: 0.067
  29. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest. 2008 Jul; 118(7):2562-73.
    View in: PubMed
    Score: 0.058
  30. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Exp Hematol. 2008 Aug; 36(8):988-96.
    View in: PubMed
    Score: 0.057
  31. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005 Nov; 11(11):1244-9.
    View in: PubMed
    Score: 0.048
  32. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
    View in: PubMed
    Score: 0.048
  33. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004 Jun 15; 172(12):7393-8.
    View in: PubMed
    Score: 0.044
  34. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004 Mar 16; 101(11):3921-6.
    View in: PubMed
    Score: 0.043
  35. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003 Dec; 17(4):187-94.
    View in: PubMed
    Score: 0.042
  36. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003 Dec; 21(4):149-61.
    View in: PubMed
    Score: 0.042
  37. Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation. Blood Adv. 2023 11 28; 7(22):6936-6948.
    View in: PubMed
    Score: 0.042
  38. Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med. 2003 Jun; 141(6):365-71.
    View in: PubMed
    Score: 0.041
  39. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood. 2003 Jul 15; 102(2):429-35.
    View in: PubMed
    Score: 0.040
  40. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002 Jun; 8(6):575-81.
    View in: PubMed
    Score: 0.038
  41. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest. 2002 May; 109(9):1249-56.
    View in: PubMed
    Score: 0.038
  42. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease. Blood. 2002 Mar 01; 99(5):1825-32.
    View in: PubMed
    Score: 0.037
  43. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest. 2013 Apr; 123(4):1590-604.
    View in: PubMed
    Score: 0.020
  44. Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med. 2011 Jan 26; 3(67):67ra8.
    View in: PubMed
    Score: 0.017
  45. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008 Aug 15; 112(4):1515-21.
    View in: PubMed
    Score: 0.014
  46. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood. 2005 Jul 15; 106(2):749-55.
    View in: PubMed
    Score: 0.012
  47. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood. 2005 Mar 01; 105(5):2023-7.
    View in: PubMed
    Score: 0.011
  48. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003 Oct; 31(10):897-902.
    View in: PubMed
    Score: 0.010
  49. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood. 2003 Jul 15; 102(2):763-71.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.